FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvalsMakary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug applications process{}

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug applications processhttps://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html